• EL
  • EN

 

  • Home
  • Helios
    • About Us
    • The Board
    • Register
  • Epidemiology
  • Thanks
  • Useful tools
    • ProFaNE/FES-I
    • FRAX-WHO Fracture Risk Assessment Tool
    • GARVAN Fracture Risk Calculator
    • Cockcroft-Gault Calculator
    • BMD converter for DXA machines
  • Journal links
  • Contact Us
  • WORLD OSTEOPOROSIS DAY

    Please click here to download the press release on World Osteoporosis Day

  • Εμβολιασμός κατά της νόσου COVID-19 & Θεραπεία της οστεοπόρωσης

  • Επικαιροποίηση των Κατευθυντήριων Οδηγιών του ΕΛΙΟΣ για την αναβολική θεραπεία

  • Ομιλίες από τη διαδικτυακή επιστημονική συνάντηση ΕΛΙΟΣ-ΕΕΜΜΟ "Φθινοπωρινές Ημέρες Οστεοπόρωσης"

    https://www.youtube.com/playlist?list=PLIyNelbH5Ev8zELelhxGgulrhs6gcl8fD

  • BMD After Transitioning From Denosumab to Alendronate

  • Approval of the marketing authorisation for Evenity (romosozumab)

    Approval of the marketing authorisation for Evenity (romosozumab)
    Re-examination leads to recommendation to approve


    After re-examining its initial opinion, the European Medicines Agency has recommended approving the marketing authorisation for the medicine Evenity for the treatment of severe osteoporosis.
    The Agency had initially refused the application on 27 June 2019 for Evenity to treat osteoporosis. After re-examination, on 17 October 2019 the Agency recommended that marketing authorisation could be granted but for a restricted indication in postmenopausal women with severe osteoporosis at high risk of fracture.
    The company that applied for authorisation was UCB Pharma S.A.

Epidemiology

The economic burden of postmenopausal Osteoporosis and related fractures in Greece


A cost-effectiveness analysis of Denosumab for the treatment of postmenopausal osteoporosis in Greece

  • JMNI
  • Skeletal Health
  • HELIOS Monographs
  • CaseQuiz
  • Results of past polls
  • Past Scientific Meetings
  • Info for Patients
  • Events

Social Media

Site Map

  • Home
  • Helios
  • Epidemiology
  • Thanks
  • Useful tools
  • Journal links
  • Contact Us

Copyright © 2012-21 heliost.gr, All rights reserved./ terms of use / Contact